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CASE REPORT
Acute kidney injury following ingestion 
of plate developer (sodium metasilicate): a case 
report
B. G. A. Rathnamali1* , G. Samarajiwa1, D. D. K. Abeyratne1, G. N. D. Perera1,2 and S. B. Gunatilake1,2
Abstract 
Background: Plate developer is a chemical used in the printing industry and is a corrosive alkaline agent containing 
sodium metasilicate as the main substance. Plate developer poisoning is rare. Literature search revealed only a single 
case report of fatal sodium metasilicate poisoning (Z Rechtsmed 94(3):245–250, 1985). There are no reports of acute 
kidney injury related to ingestion of sodium metasilicate containing substances.
Case report: A 52-year-old Sri Lankan male with a history of hypertension and affective disorder presented following 
ingestion of about 150 ml of plate developer solution. He developed severe upper airway obstruction due to laryn-
geal edema and underwent tracheostomy. While in the ward he developed features of acute kidney injury with high 
serum creatinine levels and persistent hyperkalemia which necessitated temporary haemodialysis. Because of the cor-
rosive effect, he developed severe inflammation of the upper gastro intestinal tract with narrowing of esophagus and 
pyloric region, requiring feeding jejunostomy. He died while waiting for the surgery for pyloric stenosis.
Conclusions: Acute kidney injury is a potential treatable complication of plate developer poisoning other than its 
complications related to corrosive effects. Regular monitoring of renal functions in such a patient would be useful for 
early recognition of acute kidney injury.
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Background
Plate developer is a corrosive alkaline agent which is 
used as an image developer for positive working ther-
mal plates in printing industry. It is composed of sodium 
metasilicate, a proprietary modifier and water and poi-
soning with this agent is rare. Sodium metasilicate is the 
main constituent as well as the most hazardous agent. No 
reported cases were found of acute renal failure associ-
ated with ingestion of sodium metasilicate [1].
Case presentation
A 52-year-old Sri Lankan male was admitted to hospital 
30 min after ingesting about 150 ml of PD8 (plate devel-
oper) solution. He had a history of hypertension and 
affective disorder with a past history of suicide attempts. 
However, he was not on treatment for either condition 
regularly and for the 5 months preceding this admission, 
had not taken any medication. Poisoning center was con-
tacted immediately for advice. Gastric lavage or activated 
charcoal was not instituted as the poison was a corrosive 
substance.
We managed him with fluid resuscitation (using 0.9 % 
NaCl solution), soon after admission. Within first hour 
of admission, patient developed stridor and hypoxia and 
an emergency tracheostomy was done. In next 48  h we 
managed him with intravenous dexamethasone 4  mg 
8 hourly, nebulized adrenalin 4 hourly, salbutamol nebu-
lization 2  hourly, and intravenous omeprazole 40  mg 
twice daily. Blood pressure was managed with oral nifedi-
pine and prazosin and the systolic pressure remained 
above 110 mmHg and he did not become hypovolemic or 
hypotensive. A nasogastric tube was inserted to facilitate 
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removal of gastric material, and 650 ml of altered blood 
was drained. His baseline serum creatinine value was 
not known, but it rapidly deteriorated over next 72  h 
(135.8 µmol/l at 2 h, 241 µmol/l at 24 h and 650 µmol/l at 
72 h) and he developed hyperkalemia (7.2 mmol/l). It was 
initially managed with insulin-dextrose regime and cal-
cium resonium. However serum potassium level remained 
persistently above 6 mmol/l. He remained oliguric for next 
48 h despite adequate hydration and developed peripheral 
oedema and eventually pulmonary edema necessitating 
hemodialysis. His liver enzymes remained normal (aspar-
tate transaminase 37  U/L, alanine transaminase 25  U/L) 
and there was no evidence of ischemic or toxic hepatitis. 
Urine full report showed no active sediments (pus cells 
5/HPF, red cells nil, albumin nil, sugar nil, red cell casts 
nil). Chest radiography showed pulmonary edema. Hae-
modialysis was initiated on the 4th day of admission and 
repeated for the next 2 days. After the 4th haemodialysis 
serum potassium level became normal (4.7  mmol/l) and 
urine output improved. Serum creatinine declined stead-
ily during this period and haemodialysis was stopped after 
the 5th dialysis. After 1  month at the time of discharge 
his serum creatinine level was near normal (115 µmol/l). 
During the hospital stay, patient developed intolerance 
to nasogastric feeding. Upper Gastro-intestinal endos-
copy performed on day 20 revealed severe inflammation 
and narrowing of the lumen of esophagus, ulceration of 
the stomach and upper duodenum and narrowing of the 
pyloric opening. A feeding jejunostomy was done for 
enteral feeding on day 21. Patient also required blood 
transfusion to correct anaemia. Olanzapine and fluoxetine 
was started by psychiatrists for severe depression. Three 
months after discharge the jejunostomy was blocked and 
total parenteral nutrition was resorted to. He died while 
waiting for surgery to correct the pyloric stenosis from 
complications related to malnutrition.
Discussion
Plate developer poisoning is rare. This is to our knowl-
edge the first case report of acute renal failure follow-
ing ingestion of plate developer. Sodium metasilicate is a 
constituent of various products and used for various pur-
poses such as fireproofing mixtures, in laundry, for metal 
and floor cleaning, for de-inking recycled paper products 
in the pulp and paper industry, in washing carbonated 
drink bottles, in insecticides, fungicides, and antimicro-
bial compounds, and as a chemical intermediate for silica 
gel catalysts, an additive in soaps and synthetic deter-
gents, an ingredient in adhesives, a bleaching aid. Com-
bined with other salts such as sodium bicarbonate, it can 
be applied to aluminum as a paint stripper [2].
Toxicity of the sodium metasilicate depends on the 
concentration, the silica to alkali ratio, the sensitivity of 
the exposed tissue, and the length of exposure [3]. Solu-
ble silicates can induce effects ranging from irritation 
to corrosion. Sodium metasilicate can produce caustic 
burns (i.e., colliquative necrosis) and induce hypocal-
caemia by binding to calcium. In an animal study, oral 
administration of sodium metasilicate produced ulcera-
tion and bleeding in the stomach, duodenum and small 
intestine. Oral dosing of the 20 % solution caused dysp-
nea, and nasal discharge. Higher doses caused death [3].
Sodium metasilicate associated renal injury
Intraperitoneal injection of nonahydrate form of meta-
silicate to guinea pigs has shown to produce silicaceous 
deposits in the kidney tubules. This effect was also dem-
onstrated in another study in which dogs were given 
sodium metasilicate orally. Unspecified damage to kid-
neys, ureters, bladder, gastrointestinal tract, and the 
lungs were observed. When it was given orally to rats, 
slight degenerative changes in the epithelia of the renal 
tubules were observed [3].
Available human data also showed that oral administra-
tion of sodium metasilicate (TDLo = 1 mL/kg; 217 mg/
kg) produced changes in kidney tubules, hematuria and 
caused nausea or vomiting [3]. But we did not find any 
reported cases of acute renal failure. Ultra sound study 
of kidney, ureter and bladder performed on the third 
day of admission showed normal kidney size with fea-
tures of acute kidney injury and no evidence of obstruc-
tive uropathy. His creatinine level rose rapidly within few 
days with features of acute renal failure. His blood pres-
sure remained high and it was managed with nifedipine 
and prazosin and lowest recorded blood pressure was 
110/70 mmHg. There was no period of hypovolemia and 
hypotension. We did not use any nephrotoxic medica-
tions for the management of this patient. We could not 
perform a renal biopsy at that stage as patient was not 
stable. At the time of discharge creatinine was 115 µmol/l 
and it remained same after 3  months of follow up. It is 
likely that he had developed acute kidney injury due to 
direct toxicity of metasilicate on the kidneys.
Conclusions
Clinicians should be aware that in addition to the cor-
rosive injuries to gastrointestinal tract, acute renal fail-
ure can occur following ingestion of sodium metasilicate 
containing compounds such as plate developer. There-
fore, acute renal toxicity should be anticipated in patients 
with plate developer toxicity and their renal functions 
should be monitored closely.
Abbreviations
Ml: milliliter; PD8: plate developer 8; Mg: milligram; TDLo: lowest published 
toxic dose.
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